Oil prices turn lower as Bessent says U.S. may have Iran deal "today or tomorrow"

GoodRx Holdings, Inc. (NASDAQ:GDRX) held its Annual Meeting of Stockholders on Tuesday. According to a press release statement and SEC filing, stockholders voted on three proposals. The meeting comes as the prescription savings platform trades at $2.68, which InvestingPro analysis suggests is undervalued compared to its Fair Value—placing it among stocks on the Most Undervalued list. The company maintains an impressive gross profit margin of 92% and holds a "GOOD" financial health score.

First, the election of three Class III directors for terms ending at the 2029 Annual Meeting was approved. Wendy Barnes, Ronald E. Bruehlman, and Gregory Mondre were elected. The voting results for each director were as follows: Wendy Barnes received 2,379,952,868 votes for and 10,078,860 votes withheld; Ronald E. Bruehlman received 2,380,863,641 votes for and 9,168,087 votes withheld; Gregory Mondre received 2,382,474,121 votes for and 7,557,607 votes withheld. There were 39,543,093 broker non-votes for each nominee.

Second, stockholders ratified the appointment of KPMG LLP as GoodRx Holdings’ independent registered public accounting firm for the fiscal year ending December 31, 2026. The proposal received 2,429,055,999 votes for, 335,716 votes against, and 183,106 votes abstained. There were no broker non-votes on this item.

Third, on an advisory (non-binding) basis, stockholders approved the compensation of the company’s named executive officers. This proposal received 2,363,913,370 votes for, 23,702,520 votes against, and 2,415,838 votes abstained, with 39,543,093 broker non-votes.

A total of 89,932,951 shares of Class A common stock and 233,964,187 shares of Class B common stock were present or represented by proxy at the meeting, representing approximately 99.4% of the combined voting power as of the record date of April 20, 2026.

The information in this article is based on a press release statement and the company’s filing with the Securities and Exchange Commission.

In other recent news, GoodRx Holdings, Inc. reported its first-quarter 2026 earnings, meeting earnings per share expectations at $0.07 and exceeding revenue forecasts with $194 million, representing a 4.71% surprise. In a strategic move, GoodRx launched a $14.99 monthly subscription service called GoodRx Companion, providing access to over 200 generic medications at no cost, telehealth visits, and discounts on healthcare services. Meanwhile, the Trump administration is set to expand its TrumpRx platform by adding generic medications, with Mark Cuban attending a White House event to announce the rollout.

This expansion aims to promote deals with pharmaceutical companies to reduce drug prices for government programs and direct consumer sales. In other developments, oral Wegovy prescriptions have gained significant traction, accounting for approximately 33% of total Wegovy prescriptions by May, according to a Bank of America report. The oral version, introduced in January, reached 159,000 weekly total prescriptions by early June. The mix of oral prescriptions has stabilized in the low-30% range after initial rapid growth. These recent developments highlight significant shifts in the healthcare and pharmaceutical sectors.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Is now the time to buy GDRX?

ProPicks AI evaluates GDRX every month against thousands of alternatives using 100+ financial metrics.
It found Siemens Energy (+231.5%) and Sandisk (+189%) before the crowd did. Could GDRX be next—or is there a better opportunity in the same space?
Don't wait to find out.